Skip to content

Latest news

Helsinn and Immedica enter exclusive partnership for commercialization of cancer supportive care products in core European markets

LUGANO, Switzerland and STOCKHOLM, Sweden – January 24, 2023– Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a strong focus in oncology and rare diseases, and Immedica Pharma AB, a pharmaceutical company focused on commercialisation of rare and specialty care products, today announce that the companies have

Satisfying unmet medical needs

Immedica is a fast-growing private niche pharma group. Its headquarter is based in Stockholm, Sweden, and it has commercial coverage across Europe and the Middle East.

Immedica Pharma AB
Norrtullsgatan 15
SE-113 29 Stockholm